Association of Arg389Gly β 1-adrenergic receptor polymorphism with effective dose of β blocker in congestive heart failure among Chinese Han population

Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China

Running title

β 1-adrenergic receptor polymorphism and heart failure

Authors

Rong Gu*, Yu Shen*, Jianhua Liu*, Shuaihua Qiao*, Lian Wang*, Biao Xu*

Author Affiliation

*Department of Cardiology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China

Corresponding authors at

Department of Cardiology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Zhongshan Road, Nanjing 210008, China. Tel./fax: +86 25 68182812.

Author contributions

Rong Gu and Yu Shen contributed this work equally. Lian Wang and Biao Xu are co-corresponding authors. Rong Gu, Yu Shen, Lian Wang and Biao Xu conceived and organized the project and wrote the manuscript. Jianhua Liu and Shuaihui Qiao contributed to experiments and data analysis. All authors discussed the results and commented on the manuscript.

1 Abstract

2 **Background:** To investigate the relationship between β 1-adrenergic receptor
3 (ADRB1) gene polymorphisms and the response to medication in patients with
4 congestive heart failure (CHF). **Methods and Results:** Two hundred and sixty
5 patients with CHF were enrolled. Ser49Gly and Arg389Gly polymorphisms were
6 identified. During one-year follow-up, differences of echocardiographic parameters
7 and major adverse cardiac events (MACE) were analyzed. For Ser49Gly
8 polymorphisms, there were no differences between AA genotype and AG/GG
9 genotype of baseline clinical features and echocardiographic parameters as well as
10 one-year incidence of MACE. For Arg389Gly polymorphisms, there were no
11 significant differences in baseline clinical characteristics, LVDd and LVEF among the
12 three genotypes. However, the increase amplitude of LVEF after one year among
13 patients carrying GG genotype was significantly higher than those carrying CC
14 genotype (11.7% vs 1.3%, $P<0.05$). The incidence of MACE among different
15 genotypes of CC, CG and GG were 22.2%, 10.0% and 8.3%, with statistical difference
16 ($P=0.021$). **Conclusions:** The study suggested there was no relationship between
17 Ser49Gly polymorphisms of the ADRB1 gene and the therapeutic effect and
18 prognosis in CHF patients under the same dosage of drugs. However, the
19 improvement of cardiac function and prognosis in patients carrying the Gly389 allele
20 were significantly better than those of Arg389Arg homozygous.

21 **Key words:** Congestive heart failure; β 1-adrenergic receptor; Gene
22 polymorphisms; Prognosis

23
24
25
26
27
28
29
30

1. Introduction

Congestive heart failure (CHF) is a complex clinical syndrome recognized as the end-stage of various cardiovascular diseases. Intensive researches have stated the excessive long-term hyperactivation of the adrenergic nervous system in CHF contributes to disease progression (1). Blockade of β 1-adrenergic receptor (ADRB1), the principal subtype of adrenergic receptor on cardiomyocytes, can improve CHF patients' prognosis.

However, pharmaceutical effects of ADRB1 blockers vary in CHF patients, which might be explained, at least in part, by genetic differences. The coding block of intron-less ADRB1 gene has two common nonsynonymous single nucleotide polymorphisms (SNPs) at nucleotides 145 and 1165(2). Gene polymorphism(rs1801252) locus at nucleic acid 145(A→G) resulted in substitution of Ser for Gly at position 49, and subsequently lead to a lower baseline activity of adenylate cyclase and activation by isoprenaline(3). Arg389Gly gene polymorphism (rs1801253) locus at position 1165, base G is replaced by C. Arg389 variant predisposes to heart failure by instigating hyperactive signaling programs leading to depressed receptor coupling and ventricular dysfunction(4).

However, so far, the results of different researches in this field were inconsistent, even paradoxical, so there is no definite conclusion to guide clinical applications(5,6). Also, few researches were performed among Chinese people.

Our study aimed to explore the relationship of ADRB1 gene polymorphism of Ser49Gly and Arg389Gly and their corresponding therapeutic response.

2. Materials and Methods

2.1. Study population

We examined 260 adult patients with CHF, who were referred to Cardiology Department, Nanjing Drum Tower Hospital between October 2013 and April 2015. Inclusion criteria: age between 18 and 80 years; etiology of CHF is either idiopathic dilated cardiomyopathy (IDCM) or ischemic heart disease (IHD) which was diagnosed by coronary angiography; left ventricular ejection fraction (LVEF) $\leq$ 40% in echocardiography; New York Heart Association (NYHA) Classification Cardiac

1 Function II-III under proper treatment. Exclusion criteria: acute myocardial infarction;
2 second or third degree atrioventricular block, sick sinus syndrome, cardiac arrest,
3 allergy to β receptor blocker, asthma, severe kidney or liver dysfunction, malignant
4 tumor, life expectancy <1 year and cardiac resynchronization therapy with pacemaker
5 function (CRT-P) or cardiac resynchronization therapy with defibrillator
6 function (CRT-D) implantation within 1 year.

7 **2.2. Automated DNA sequence analysis**

8 Genomic DNA was extracted from peripheral blood utilizing DP348 kit (Tiangen,
9 China). Polymerase chain reaction (PCR) was performed to amplify 2 fragments
10 encompassing the entire ADRB1 gene. The PCR fragments were then purified and
11 subjected to cycle sequencing by overlapping primers and the ABI PRISM BigDye
12 Terminator Ready Reaction Mix (Applied Biosystems, USA). Genotyping for Codon
13 49 and Codon 389 of ADRB1 were performed with achieved DNA by TaqMan Assay
14 (Thermo Fisher, USA). For Codon 49 polymorphism of ADRB1, the corresponding
15 base of Ser49Ser was AA, Ser49Gly was AG and Gly49Gly was GG; and the forward
16 primer used was 5'-CCGGGCTTCTGGGGTGTTC-3' and the reverse primer was
17 5'-GGCGAGGTGATGGCGAGGTAGC-3'. For the polymorphism of Codon 389, the
18 corresponding base of Arg389Arg was CC, Arg389Gly was CG and Gly389Gly was
19 GG; and the forward primer was 5'-CGCTCTGCTGGCTGCCCTTCTTC-3' and the
20 reverse primer was 5'-TGGGCTTCGAGTTCACCTGCTATC-3'.

21 **2.3. Clinical data collection**

22 Patients continued pharmacotherapy in outpatient clinic, and the average follow-up
23 period was 1 year. All β -receptor blocker used in this study was metoprolol tablets or
24 metoprolol sustained-release tablets. Aldosterone antagonist used was spiro lactone.
25 The use of ACEI or ARB was decided individually by physicians according to
26 patients' condition. Patients' baseline data, including age, gender, CHF etiology,
27 hypertension, diabetes, smoking habit, creatinine level, BNP, heart rate, and NYHA
28 Classification were all obtained through electronic medical record. Major adverse
29 cardiac events (MACE) were defined as cardiac death, heart transplantation,

malignant arrhythmia, rehospitalization due to CHF. 3-month, 6-month and 1-year follow-up were completed through outpatient clinic, returning visit or telephone follow-up.

2.4. Statistical analysis

All statistical analyses were performed with SPSS statistical software (version 20.0, Chicago, USA). Quantitative data were expressed as mean $\pm$ SD. One-way ANOVA was performed to compare among three groups; independent sample *t*-test was performed to compare between two groups; rank-sum test was performed to compare NYHA Classification. Enumeration data was compared with chi-squared test.

3. Results

3.1. Baseline Clinical Characteristics

We recruited 260 CHF patients, among which 163 patients (including 121 male and 42 female) have completed full medical records and 1-year follow-up. Mean age was 62.2 ± 15.4 years; baseline heart rate was 78.5 ± 14.0 bpm. Among these patients, 125 patients was diagnosed IHD; 79 had a history of hypertension; 42 had diabetes; 63 were smokers. There were no significant differences in gender, CHF etiology, and medical history across different genotypes.

3.2. Interaction between Codon 49 genotype and treatment

The analysis results of Codon 49 genotype was shown in figure 1A. As shown in Table 1 and 2, there was no significant difference in baseline characteristics, echocardiographic data and pharmacotherapy during 1-year follow-up period ($P > 0.05$). Compared with the G-allele carriers, a homozygote tended to obtain better systolic function recovery and more left ventricular size reduction according to echocardiography within 12-months follow-up; however, they were not statistically different (Figure 2 and Table 3 and 4). 1-year MACE incidence among patients with AA genotype was 13.7%; whereas, it was 21.4% among G-allele carriers ($P = 0.208$).

3.3. Interaction between Codon 389 genotype and treatment

The analysis results of Codon 389 genotype was shown in figure 1B. There were no significant difference between different genotypes of Codon 389 in baseline characteristics, echocardiography and pharmacotherapy ($P > 0.05$, Table 5 and 6).

During the whole study, patients carrying G homozygous gene tended to have better EF and left ventricular size improvement compared with C-allele carriers (Figure 3A,3B,3C and Table 7). In further analysis shown in Table 8, Figure 3D,3E and 3F, patients with GG genotype responded better to pharmacotherapy, especially when comparing with those with CC genotype, as shown in EF increase ($P = 0.000$), LVDd reduction ($P = 0.007$) and LVDs reduction ($P = 0.001$), at 12-month time point. Towards the end of the study, similar favorable responses among CG genotype were observed comparing with CC genotype, as shown in EF increase ($P = 0.019$) and LVDs reduction ($P = 0.020$).

As shown in Table 9, participants carrying GG genotype have the lowest MACE incidence ($P < 0.05$) comparing with other genotypes. 1-year MACE incidence among G allele carriers was 9.7%, significantly lower than that among CC genotype ($P = 0.006$).

4. Discussion

Sympathetic-adrenergic system activation is one of the most important compensatory mechanism of CHF which can ameliorative hemodynamic instability, by increasing myocardial contractility and decreasing left ventricular diastolic pressure in the early-phase(1). However, the long-lasting hyperactivation of sympathetic-adrenergic system would induce cardiomyocytes apoptosis, accelerate cardiac remodeling, and down-regulate β -receptor density(1). Substantial researches have demonstrated that β blockers can reduce cardiovascular mortality, incidence of sudden cardiac death and rehospitalization; therefore, the use of β blockers have been recommended as the standard therapeutic medication in all CHF patients by most guidelines(7).

Previous researches demonstrated that gene polymorphisms involved in catecholamine signaling might modulate CHF progression and patients' response to therapy(2); however, the results are often controversial. So there are no definite conclusions to guide clinic applications yet; also, most of these studies were completed among Caucasians or Americans, but rarely Asians(6).

The two primary SNPs of ADRB1 gene are Ser49Gly and Arg389Gly gene polymers. SNP of Arg389Gly in ADRB1 is in intracellular C-terminus, which is an

1 important site for G-protein binding. Arg389, which occurs in 20% - 30% of Asians,
2 has higher basal and isoprenaline-stimulated adenylate cyclase activity, decreased
3 G-protein coupling and reduced β blocker responses. The impact of Arg389Gly on β
4 blocker responses and CHF prognosis were inconsistent in clinical trials.
5 Improvement of cardiac function(4), reduced mortality(5) and higher exercise
6 capacity(8) were observed among CHF patients with Arg389 genotype. However,
7 patients with Gly389X genotype showed greater response to bisoprolol than the
8 Arg389Arg genotype in ABBA study(9), but no response to β blocker treatment in
9 subgroup analysis of MERIT-HF study(10).

10 Two fundamental researches observed the different influence of Arg389Gly gene
11 polymorphisms of ADRB1 gene on positive inotropic effect of norepinephrine in
12 human atrial myocardium as well: Sandilands et al.(11) found that patients with
13 Arg389 genotype had stronger inotropic effect and cyclicadenosine monophosphate
14 (cAMP) reaction to norepinephrine than other genotypes; while Molenaar et al.(12)
15 did not find such inotropic effects among patients with Arg389 genotype.

16 In our study, the increase of LVEF, the decrease of left ventricular end-diastolic
17 dimension (LVDd) and left ventricular end-systolic dimension (LVDs) of patients
18 with GG allele was obviously higher than those with CC allele. At 1-year follow-up,
19 the MACE incidence of patients with G allele was obviously lower. From all the
20 above results, we concluded that patients carrying Gly389 gene are more likely to
21 gain more pronounced therapeutic effects of β blocker, better improvement of cardiac
22 function and more promising prognosis. Similarly, another Korean study published in
23 2016 found that Gly389 carriers were more sensitive to bisoprolol and had better
24 prognosis comparing with patients with Arg389Arg(9). Biolo A et al. found that
25 Gly389 carriers had better prognosis and higher survival rate in 2008(13) and
26 2010(14). Also, HF-ACTION DNA substudy showed that patients with Arg389Arg
27 allele need higher dosage of β blocker than other genotypes in CHF patients(15).
28 These results are all in accordance with our results.

29 The functional consequences of Gly49 genotype, which occurs in the N-terminus
30 region of 14% Asian people, are involved in receptor down-regulation as well as in

intracellular trafficking(16). In 2002, Rathz et al.(17) found the affinity to agonist and antagonist of both gene variants were similar; however, Gly49 presented with a more significant receptor down-regulation with long-termagonist treatment compared with Ser49. Also in 2002, Levin MC et al found the adenylate cyclase activity of patients with Gly49 genotype was higher than those with Ser49 while it was more sensitive to inhibitor such as metoprolol(3). The more common Ser49Ser genotype responded less beneficially to β blockers, and this would motivate genotyping to guide doctors to give higher doses for a better clinical outcome(18).

Our study found that there was no statistic difference in cardiac function changes and MACE incidence between different genotypes of Codon 49. It implied that Ser49Gly polymorphism had no obvious influence on therapeutic effects and patients' prognosis, which is in consistence with the conclusion of Humma's research(19).

This is a retrospective study, so we can not titrage the dosage of β blocker. However, in our study, there is no difference of the dosage of β blocker in patients with different genotypes at 1 year, while the therapeutic effects were obviously worse among patients with CC than those with GG allele, also slightly worse that those with CG allele. We inferred that, if possible, in order to achieve the best therapeutic effect, larger dose of β blocker is required among patients with CC genotype.

Considering CRT-P and CRT-D have some effects on cardiac function of CHF patients, and the treatment of valvular heart disease is mainly depend on surgery instead of drug therapy, our study exclude the above-mentioned cases.

5. Conclusions

Our study concluded that Arg389Gly β 1-adrenergic receptor polymorphism is related to β blockers' therapeutic effect and prognosis of CHF, but not Ser49Gly. With the same dosage of CHF drugs, the improvement of cardiac function and prognosis of patients with Gly389 allele is obviously better than those carrying CC homozygote. This provided a possible gene-related individualized therapeutic plan among CHF patients.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grant number 81200092); foundation of the health department of Jiangsu Province (grant number z201514); Nanjing Medical Science and Technique Development Foundation (grant number ZKX13023).

References

- (1) Lymperopoulos A, Rengo G, and Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. *Circ Res* 2013; **113**: 739-53.
- (2) Shin J, and Johnson JA. Beta-blocker pharmacogenetics in heart failure. *Heart Fail Rev* 2010; **15**: 187-96.
- (3) Levin MC, Marullo S, Muntaner O, *et al.* The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. *J Biol Chem* 2002; **277**: 30429-35.
- (4) Mialet Perez J, Rathz DA, Petrashevskaya NN, *et al.* Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. *Nat Med* 2003; **9**: 1300-5.
- (5) Liggett SB, Mialet-Perez J, Thaneemit-Chen S, *et al.* A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. *Proc Natl Acad Sci U S A* 2006; **103**: 11288-93.
- (6) Muthumala A, Drenos F, Elliott PM, *et al.* Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. *Eur J Heart Fail* 2008; **10**: 3-13.
- (7) Fleg JL, Pina IL, Balady GJ, *et al.* Assessment of functional capacity in clinical and research applications: an advisory from the committee on exercise,

- 1 rehabilitation, and prevention, council on clinical cardiology, American Heart
- 2 Association.*Circulation*2000; **102**: 1591-7.
- 3 (8) Wagoner LE, Craft LL, Zengel P,*et al.* Polymorphisms of the beta1-adrenergic
- 4 receptor predict exercise capacity in heart failure.*Am Heart J*2002; **144**: 840-6.
- 5 (9) Lee HY, Chung WJ, Jeon HK, *et al.* Impact of the beta-1 adrenergic receptor
- 6 polymorphism on tolerability and efficacy of bisoprolol therapy in Korean
- 7 heart failure patients: association between beta adrenergic receptor
- 8 polymorphism and bisoprolol therapy in heart failure (Abba) Study.*Korean J*
- 9 *Intern Med*2016; **31**: 277-87.
- 10 (10) White HL, de Boer RA, Maqbool A,*et al.* An evaluation of the beta-1
- 11 adrenergic receptor Arg389gly polymorphism in Individuals with heart failure:
- 12 a Merit-Hf sub-study.*Eur J Heart Fail*2003; **5**: 463-8.
- 13 (11) Sandilands AJ, O'Shaughnessy KM, and Brown MJ. Greater inotropic and
- 14 cyclic amp responses evoked by noradrenaline through Arg389 beta
- 15 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial
- 16 myocardium.*Br J Pharmacol*2003; **138**: 386-92.
- 17 (12) Molenaar P, Rabnott G, Yang I,*et al.* Conservation of the cardiostimulant
- 18 effects of (-)-norepinephrine across Ser49gly and Gly389arg
- 19 beta(1)-adrenergic receptor polymorphisms in human right atrium in vitro.*J*
- 20 *Am Coll Cardiol*2002; **40**: 1275-82.
- 21 (13) Biolo A, Clausell N, Santos KG, *et al.* Impact of Beta1-adrenergic receptor
- 22 polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis,
- 23 and response to beta-blocker therapy.*Am J Cardiol*2008; **102**: 726-32.
- 24 (14) Biolo A, Salvaro R, Clausell N,*et al.* Impact of beta-2 Thr164ile and combined
- 25 beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart
- 26 failure outpatients.*Braz J Med Biol Res*2010;**43**: 565-71.
- 27 (15) Fiuzat M, Neely ML, Starr AZ,*et al.* Association between adrenergic receptor
- 28 genotypes and beta-blocker dose in heart failure patients: analysis from the
- 29 hf-action DNA substudy.*Eur J Heart Fail*2013;**15**: 258-66.
- 30 (16) von Homeyer P and Schwinn DA. Pharmacogenomics of beta-adrenergic

- 1 receptor physiology and response to beta-blockade.*Anesth Analg*2011; **113**:
- 2 1305-18.
- 3 (17) Rathz DA, Brown KM, Kramer LA,*et al.* Amino acid 49 polymorphisms of
- 4 the human beta1-adrenergic receptor affect agonist-promoted trafficking..*J*
- 5 *Cardiovasc Pharmacol*2002; **39**: 155-60.
- 6 (18) Magnusson Y, Levin MC, Eggertsen R,*et al.* Ser49gly of beta1-adrenergic
- 7 receptor Is associated with effective beta-blocker dose in dilated
- 8 cardiomyopathy..*Clin Pharmacol Ther*2005; **78**: 221-31.
- 9 (19) Humma LM, Puckett BJ, Richardson HE,*et al.* Effects of beta1-adrenoceptor
- 10 genetic polymorphisms on resting hemodynamics in patients undergoing
- 11 diagnostic testing for ischemia..*Am J Cardiol* 2001;**88**: 1034-7.

1 **Figure legends**

2 **Figure 1.** Taqman analysis of β 1-adrenoreceptor gene polymorphism.

3 A: Taqman analysis of Codon 49; B: Taqman analysis of Codon 389.

4 **Figure 2.** Interaction between Codon 49 genotype of β 1-adrenoceptor gene and
5 echocardiographic data.

6 EF, ejection fraction; LVDd, left ventricular end-diastolic dimension; LVDs, left
7 ventricular end-systolic dimension.

8 **Figure 3.** Interaction between Codon 389 genotype of β 1-adrenoceptor gene and
9 echocardiographic data.

10 EF, ejection fraction; LVDd, left ventricular end-diastolic dimension; LVDs, left
11 ventricular end-systolic dimension.

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

1

Table 1. Baseline characteristics

	Codon 49		<i>P</i> value
	AA (n = 128)	AG/GG (n = 35)	
Age (years)	62.8 ± 15.5	60.2 ± 14.8	0.384
Male (%)	73.4	77.1	0.828
Etiology (IDCM,%)	78.9	68.6	0.258
Hypertension (%)	49.2	45.7	0.699
Diabetes (%)	27.3	20.0	0.369
Smoke (%)	39.1	37.1	0.843
Creatinine (μmol/L)	95.1 ± 42.1	90.5 ± 30.6	0.584
BNP (pg/mL)	972.9 ± 984.7	769.4 ± 634.9	0.357
Heart rate (bpm)	78.3 ± 14.9	79.2 ± 15.2	0.784
NYHA Classification			
ClassII	31 (24.2%)	11 (31.4%)	0.218
ClassIII	47 (36.7%)	14 (40.0%)	
Echocardiography			
EF (%)	31.2 ± 5.9	31.4 ± 7.0	0.831
LVDd (mm)	67.8 ± 8.9	67.7 ± 8.4	0.952
LVDs (mm)	57.6 ± 9.3	57.8 ± 9.2	0.891
IVSTd (mm)	8.5 ± 1.5	8.4 ± 1.4	0.714
LVPWTd (mm)	8.6 ± 1.3	8.6 ± 1.2	0.735
LAD (mm)	50.5 ± 8.4	50.3 ± 8.0	0.920
Pharmacotherapy			
ACEI/ARB (%)	88.3	82.9	0.385
β-receptor blocker (%)	92.2	88.6	0.452
Metoprolol (mg)	45.9 ± 34.7	52.8 ± 34.8	0.340
Aldosterone antagonist (%)	93.8	91.4	0.764
Spirolactone (mg)	20.1 ± 6.5	20.0 ± 0.0	0.962

1 IDCM, idiopathic dilated cardiomyopathy; BNP, brain natriuretic peptide; NYHA,
 2 New York Heart Association; EF, ejection fraction; LVDd,
 3 left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension;
 4 IVSTd, interventricular septum thickness at end-diastole; LVPWTd, left ventricular
 5 posterior wall thickness at end-diastole; LAD, left atrial diameter; ACEI,
 6 angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.

7

8 **Table 2. Pharmacotherapy within 1-year follow-up**

	Ser49Gly		P value
	AA (n = 128)	AG/GG (n = 35)	
3months			
ACEI/ARB (%)	92.2%	91.4%	0.589
β-receptor blocker (%)	95.3%	94.3%	0.871
Metoprolol (mg)	50.6 ± 40.7	54.2 ± 37.7	0.417
Aldosterone antagonist (%)	94.5%	91.4%	0.436
Spirolactone (mg)	20.2 ± 4.3	20.0 ± 0.0	0.536
6months			
ACEI/ARB (%)	93.8%	94.3%	0.518
β-receptor blocker (%)	96.9%	97.1%	0.389
Metoprolol (mg)	51.2 ± 38.8	53.4 ± 39.2	0.875
Aldosterone antagonist (%)	96.1%	94.3%	0.298
Spirolactone (mg)	20.4 ± 3.1	20.2 ± 2.1	0.901
12months			
ACEI/ARB (%)	96.1%	97.1%	0.629
β-receptor blocker (%)	97.7%	97.1%	0.634

Metoprolol (mg)	49.8 ± 41.1	52.1 ± 40.2	0.510
Aldosterone antagonist (%)	96.1%	94.3%	0.398
Spirolactone (mg)	20.6 ± 2.8	20.1 ± 1.8	0.878

1 ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.

2

3 **Table 3. Echocardiography within 1-year follow-up**

		Ser49Gly	
Time		AA (n = 128)	AG/GG (n = 35)
EF (%)	3months	32.9 ± 7.0	31.5 ± 6.7
	6months	34.1 ± 8.1	31.8 ± 6.9
	12months	35.3 ± 9.9	32.3 ± 7.4
LVDd (mm)	3months	67.1 ± 8.9	67.7 ± 8.0
	6months	66.5 ± 9.2	67.6 ± 8.1
	12months	65.8 ± 9.9	67.3 ± 8.4
LVDs (mm)	3months	56.4 ± 9.6	57.7 ± 9.1
	6months	55.6 ± 10.2	57.4 ± 9.0
	12months	54.8 ± 11.1	56.9 ± 9.4

4 EF, ejection fraction; LVDd, left ventricular end-diastolic dimension; LVDs, left
5 ventricular end-systolic dimension.

6

7 **Table 4. Echocardiography within 1-year follow-up**

		Codon 49		
Time		AA (n = 128)	AG/GG (n = 35)	P value
EF increase (%)	3months	1.8 ± 5.0	0.1 ± 1.8	0.078
	6months	2.9 ± 6.8	0.4 ± 2.9	0.217
	12months	4.0 ± 9.1	0.9 ± 4.9	0.203

LVDd reduction (mm)	3months	0.6 ± 2.6	0.1 ± 1.6	0.229
	6months	1.2 ± 4.3	0.2 ± 2.2	0.602
	12months	2.0 ± 6.1	0.4 ± 3.1	0.461
LVDs reduction (mm)	3months	1.1 ± 3.7	0.1 ± 1.3	0.178
	6months	2.0 ± 5.4	0.4 ± 2.3	0.430
	12months	2.8 ± 7.3	1.0 ± 3.9	0.394

1 EF, ejection fraction; LVDd, left ventricular end-diastolic dimension; LVDs, left
2 ventricular end-systolic dimension.

3

4 **Table 5. Baseline characteristics**

	Codon 389			<i>P</i> value
	CC (n = 79)	CG (n = 69)	GG (n = 15)	
Age (years)	64.2 ± 15.1	61.1 ± 16.0	56.7 ± 12.3	0.157
Male (%)	65.8%	82.6%	80%	0.463
Etiology (IDCM ,%)	77.2%	76.8%	73.3%	0.948
Hypertension (%)	53.2%	43.5%	46.7%	0.515
Diabetes (%)	30.4%	21.7%	20%	0.233
Smoke (%)	46.8%	29%	40%	0.069
Creatinine (umol/L)	98.2 ± 49.2	87.6 ± 25.4	102.2 ± 34.8	0.253
BNP (pg/mL)	986.7 ± 1103.1	905.8 ± 768.9	799.6 ± 711.2	0.814
Heart rate (bpm)	78.6 ± 15.9	79.1 ± 13.7	74.9 ± 15.2	0.653
NYHA Classification				0.096
Stage II	17 (21.5%)	18 (26.1%)	6 (40.0%)	
Stage III	32 (40.5%)	22 (31.9%)	7 (46.6%)	
Echocardiography				
EF (%)	31.7 ± 6.2	31.5 ± 5.8	27.6 ± 6.4	0.051
LVDd (mm)	68.2 ± 8.4	66.8 ± 9.3	70.0 ± 7.8	0.358

LVDs (mm)	58.1 ± 8.8	56.4 ± 9.8	60.9 ± 8.6	0.206
IVSTd (mm)	8.6 ± 1.6	8.4 ± 1.3	8.3 ± 1.5	0.432
LVPWTd (mm)	8.8 ± 1.4	8.4 ± 1.0	8.3 ± 1.1	0.101
LAD (mm)	51.0 ± 8.9	49.7 ± 7.9	50.4 ± 6.5	0.644
Pharmacotherapy				
ACEI/ARB (%)	87.3%	87%	86.7%	0.895
β-receptor blocker (%)	92.4%	91.3%	86.7%	0.689
Metoprolol (mg)	44.7 ± 32.0	48.2 ± 34.9	57.5 ± 47.0	0.467
Spirolactone (%)	93.7%	94.2%	86.7%	0.663
Spirolactone (mg)	20.3 ± 2.5	21.5 ± 8.6	20.0 ± 0.0	0.479

1 IDCM, idiopathic dilated cardiomyopathy; BNP, brain natriuretic peptide; NYHA,
2 New York Heart Association; EF, ejection fraction; LVDd,
3 left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension;
4 IVSTd, interventricular septum thickness at end-diastole; LVPWTd, left ventricular
5 posterior wall thickness at end-diastole; LAD, left atrial diameter; ACEI,
6 angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.

7

8 **Table 6. Pharmacotherapy within 1-year follow-up**

	Codon 389			<i>P</i> value
	CC (n = 79)	CG (n = 69)	GG (n = 15)	
3months				
ACEI/ARB (%)	92.4%	92.8%	93.3%	0.647
β-receptor blocker (%)	95.0%	92.8%	93.3%	0.712
Metoprolol (mg)	49.3 ± 34.2	51.6 ± 36.6	58.2 ± 45.8	0.367
Spirolactone (%)	93.7%	94.2%	93.3%	0.634
Spirolactone (mg)	20.7 ± 3.0	20.8 ± 5.3	20.0 ± 0.0	0.887
6months				

ACEI/ARB (%)	95.0%	94.2%	93.3%	0.299
β-receptor blocker (%)	97.5%	97.1%	100.0%	0.310
Metoprolol (mg)	51.2 ± 36.0	50.3 ± 37.4	56.5 ± 44.2	0.276
Spirolactone(%)	96.2%	95.7%	93.3%	0.421
Spirolactone(mg)	20.5 ± 1.9	20.7 ± 4.8	20.0 ± 0.0	0.871
12months				
ACEI/ARB (%)	96.2%	97.1%	93.3%	0.429
β-receptor blocker (%)	97.5%	97.1%	100.0%	0.587
Metoprolol (mg)	50.7 ± 35.8	51.6 ± 38.1	56.3 ± 42.1	0.301
Spirolactone(%)	95.0%	95.7%	93.3%	0.410
Spirolactone (mg)	20.6 ± 2.8	20.2 ± 1.7	20.0 ± 0.0	0.892

1 ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.

2

3 **Table 7. Echocardiography within 1-year follow-up**

		Codon 389		
	Months	CC (n = 79)	CG (n = 69)	GG (n = 15)
EF (%)	3	32.3± 6.5	32.9± 6.4	33.2± 11.3
	6	32.6± 7.0	34.2± 7.6	36.3± 11.9
	12	33.0± 8.3	35.5± 9.5	39.3± 13.6
LVDd (mm)	3	67.9± 8.2	66.3± 9.1	67.6± 9.5
	6	67.8± 8.4	65.8± 9.5	65.5± 9.2
	12	67.6± 8.9	65.0± 9.9	63.0± 10.6
LVDs (mm)	3	57.4± 8.9	55.6± 9.8	57.0± 11.3
	6	57.3± 9.2	54.9± 10.3	54.3± 12.0
	12	57.0± 9.9	54.1± 10.9	51.3± 13.4

4 ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.

5

6 **Table 8. Echocardiography within 1-year follow-up**

Months	Codon 389	P value
--------	-----------	---------

		CC (n = 79)	CG (n = 69)	GG (n = 15)	
EF increase (%)	3	0.6± 2.9	1.5± 4.1	5.6± 9.5	0.005
	6	0.9± 4.5	2.7± 6.3	8.7± 9.8	0.000
	12	1.3± 6.7	4.0± 8.5	11.7± 11.5	0.000
LVDd reduction (mm)	3	0.1± 2.2	0.5± 1.9	2.5± 4.3	0.104
	6	0.3± 3.6	1.1± 3.5	4.6± 5.7	0.010
	12	0.6± 4.5	1.7± 5.3	7.1± 9.0	0.007
LVDs reduction (mm)	3	0.4± 2.9	0.9± 2.7	3.9± 6.3	0.026
	6	0.6± 4.1	1.7± 4.5	6.6± 7.5	0.002
	12	1.0± 5.3	2.3± 6.4	9.6± 10.0	0.001

1 EF, ejection fraction; LVDd, left ventricular end-diastolic dimension; LVDs, left
2 ventricular end-systolic dimension.

3

4

Table 9. MACE within 1-year follow-up

Genotype of Codon 389	1-year MACE	<i>P</i> value	
CC (n = 126)	22.2%	CC <i>vs</i> CG	0.009
CG (n = 110)	10.0%	CC <i>vs</i> GG	0.094
GG (n = 24)	8.3%	CG <i>vs</i> GG	0.803
<i>P</i> value	0.021		

5

6

7

8

9

10

11

12

13

14

Figure 1

1 **Figure 2**

1 **Figure 3**

2

3